
Opinion|Videos|January 17, 2025
ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas
Panelists discuss key factors in deciding between monotherapy and combination approaches for bispecific therapies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) as well as the potential for combination therapies to be more viable in certain B-cell lymphoma subtypes.
Advertisement
Video content above is prompted by the following:
- With several abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024 studying bispecific therapies in combination with conventional chemotherapy regimens, what factors should clinicians consider when deciding between monotherapy and combination approaches for bispecifics in FL and DLBCL?
- Do you see combination therapies with bispecifics as more viable in certain subtypes of B-cell lymphoma compared with others? Why or why not?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Colon Cancer Recurrence Risk Nearly Gone After 6 Years, Study Reveals
3
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
4
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
5